本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
TAIPEI, June 6, 2025 /PRNewswire/ -- On the opening day of Medical Taiwan 2025, Mosaic Venture Lab, as a partner of the M-novator, is dedicated to acting as a bridge connecting Taiwan's and international innovative energy. Through its investment and ecosystem collaboration platform, it accelerates the growth of global high-quality startups in Taiwan, fosters cross-border collaborations, and brings more international funding and business opportunities to Taiwan's smart healthcare industry. M-novator Demo Day Keynote Speakers and and Expert Panelists (left to right): Johnny Yu, Yenchen Huang, Jowy Tani, Nina Feng, Ryan Jin. The M-novator startup teams hail from Taiwan, the United States, South Korea, Belgium, and Israel. Examples include US-based InFocus Therapeutics, which focuses on developing RNA-targeted drugs, and Taiwan's own Pulxion, which has made breakthroughs in AI carotid artery detection, showcasing the international vitality of medical innovation. These pioneering startups, whose technologies represent cutting-edge advancements in the medical field, showcased in their Demo Day pitches precision artificial intelligence for diagnostics and data analysis, intuitive digital health platforms, seamless integration of medical devices (such as advanced endoscopes and smart wearables), and data-driven clinical decision support tools. A key theme of Medical Taiwan 2025 is the significant contribution of ecosystem builders in nurturing early-stage startups to achieve global impact. Johnny Yu, Founder and Chairman of CellTech Innovation Venture Studio and Managing Director of Mosaic Venture Lab, delivered a keynote speech on global MedTech trends and pressures, covering population aging, complex regulatory frameworks, and lengthy development cycles. Johnny highlighted key obstacles faced by early-stage startups: the lab-to-market translation gap, complex regulatory hurdles, funding constraints, and the complexities of market entry. He emphasized that ecosystem builders such as accelerators, venture studios, academic incubators, and government innovation departments play a crucial role in overcoming these challenges. Ryan Jin, Manager at Singapore's Centre for Healthcare Innovation, emphasized in his speech that while innovation is crucial, its effective integration into existing healthcare systems requires strategic partnerships. He acknowledged the common difficulties in collaboration between startups and healthcare institutions, citing systemic misalignments, "last-mile" barriers, and a lack of bridging infrastructure. To overcome these issues, Ryan stressed the need for streamlined processes, strong support for innovation adoption, and the establishment of clear communication channels. A highlight of the Demo Day, the panel discussion "Navigating Taiwan's MedTech Ecosystem" featured panelists including Jowy Tani, CEO of Taipei Medical University BioMed Accelerator; Nina Feng, Managing Director of Vivo Capital Taiwan; and Yenchen Huang, Vice President of Diamond Biofund. The panel aims to provide actionable insights for international MedTech and AI startups seeking to enter and thrive in the Taiwanese and Asian markets, focusing on strategies for clinical adoption, supply chain collaboration, and market entry. Mosaic Venture Lab is a venture capital accelerator focused on digital health, smart mobility, and semiconductor innovation. It collaborates with global automotive OEMs and Tier-1 suppliers to drive technological innovation and optimize business models, and is dedicated to discovering and nurturing innovative technologies from Taiwan, Japan, and South Korea to connect with major European and American companies. Media Contact:Jade ChengSr. Project ManagerMosaic Venture Lab - Partner of Medical Taiwan 2025 M-novatorEmail: jc@mvl.bizEvent Website: https://www.medicaltaiwan.com.tw/
Duke-NUS Medical School's Class of 2025 graduates 121 medical and doctoral students, including MDs, MD-PhDs, PhDs, and masters' degrees Landmark first batch of Masters in Patient Safety and Healthcare Quality graduates, unique to Southeast Asia Inaugural graduates from conditional admissions pathways with NUS and SUTD 41% of MD and MD-PhD graduates made bold mid-career shifts from fields such as law, PR, accounting and mental health support SINGAPORE, May 31, 2025 /PRNewswire/ -- Celebrating 20 years of transformative medical education, Duke-NUS Medical School graduated its largest cohort yet today, the Class of 2025, in a vibrant ceremony at the Ngee Ann Kongsi Auditorium in Academia attended by guest-of-honour Mr Ong Ye Kung, Minister for Health. Mr Ong Ye Kung, Minister for Health, poses for a picture with some graduates of the Duke-NUS Medical School Class of 2025, including MDs, MD-PhDs and PhDs // Photo Credit: Duke-NUS Medical School Marking a strategic milestone for Duke-NUS, the graduating class included 72 Doctor of Medicine (MD) graduates—five of whom are also earning PhDs—and 27 PhD candidates from the Integrated Biology and Medicine, Quantitative Biology and Medicine and Clinical and Translational Sciences programmes. Among the MD graduates was the first group of individuals emerging from the Duke-NUS conditional admissions pathways with the National University of Singapore (NUS) and the Singapore University of Technology and Design (SUTD). These pathways are designed to attract talent from engineering, information technology and other undergraduate programmes. Dean Professor Thomas Coffman said: "Collaborating with seven partner universities, including Duke University and NUS, these pathways are designed to allow students to earn a first degree in diverse academic majors while providing an opportunity to seamlessly transition into medicine. It's a powerful model for developing doctors who are outstanding clinicians but also bring valuable multi-disciplinary skills into our healthcare system." This cohort also includes the inaugural batch of graduates of the Master's in Patient Safety and Healthcare Quality (MPSHQ) programme, the first of its kind in Southeast Asia. The MPSHQ is focused on building highly reliable healthcare systems that are of consistent quality and safety. The Class of 2025 represents Duke-NUS' commitment to broadening the skillset and experience of our students, with 41 per cent of MD and MD-PhD graduates having transitioned mid-career from professions that include law, public relations, accounting and mental health peer support. Additionally, 58 per cent of the Class of 2025's graduates are women, underscoring the School's dedication to fostering diversity in the learning environment. Said Dr Faith Wong Pih Yng, previously a modelmaking student and senior peer support specialist at Singapore's Institute of Mental Health, now MD graduate, "Among the many hospital postings, what stood out most vividly was assisting in and witnessing childbirth—the intense anticipation and joy of welcoming a new life into the world was simply unmatched. Ultimately, however, the memories I cherish most are the countless hours spent with my classmates, supporting one another and peer-teaching." Duke-NUS MD graduates received their degrees, awarded jointly by Duke University and the National University of Singapore, in front of friends and family, as well as notable guests, including Duke University School of Medicine Dean Professor Mary Klotman, SingHealth Group CEO Professor Ng Wai Hoe, and keynote speaker, Dr Amy Abernethy, member of Duke University's board of trustees and co-founder of Highlander Health. Caring and compassion underlines the Class of 2025's accomplishments, especially beyond academia. Partaking in a wealth of community service projects, some of their cohort, such as Dr Dana Chow Wai Shin, MD, started the Healthy to Thrive initiative, the first Duke-NUS-led public health screening event dedicated to migrant workers. The cohort was also recognised for their outstanding achievements, which were given out the night before. Awards such as the Singapore Medical Association-Lee Foundation Prizes and Teamsmanship Awards presented to graduates who demonstrated excellence in academics, community service, and leadership. In the aspect of research and scholarship, the Class of 2025 did not flag, publishing an exceptional 253 papers and publications in their time at Duke-NUS, several as first authors in prominent journals such as Nature Medicine, Immunity and EMBO Molecular Medicine. MD-PhD graduate Dr Katherine Nay Yaung, first author on a paper published in Lancet Rheumatology, wrote about artificial intelligence and high-dimensional technologies to diagnose and treat autoimmune diseases, and PhD graduate Dr Aishwarya Prakash, named first author and published in American Heart AssociationJournal, who found a type of peptide to have protective qualities for the heart after sustaining damage. "The conversations I've had with patients emphasise a shift towards continuity of care and empowering individuals to make their own health choices. In moments where I feel overwhelmed, I remind myself that being a small part of each patient's journey has been a privilege," said Dr Pang Wui Ming Jeremy, recipient of the SingHealth Prize in Family Medicine, Singapore Medical Association-Lee Foundation Teamsmanship Award for exemplary team values in medicine and Duke-NUS Achievement Prize. As Duke-NUS enters its third decade, the School continues to redefine medical education and research, nurturing the next generation of healthcare leaders who are not just exceptional doctors but visionary innovators ready to make an impact in Singapore and beyond. About Duke-NUS Medical School Duke-NUS is Singapore's flagship graduate-entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted 'Clinicians Plus' poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five Signature Research Programmes and ten Centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore's largest healthcare group. This strategic alliance has led to the creation of 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives. For more information, please visit www.duke-nus.edu.sg
SINGAPORE, April 11, 2025 /PRNewswire/ -- Duke-NUS Medical School has appointed Professor Patrick Tan as its next and fourth Dean, effective 1 January 2026, marking a new chapter for the School as it builds on its legacy of medical education, research and innovation. Prof Tan will serve as Dean-designate from 1 July 2025, succeeding Professor Thomas Coffman, the School's longest-serving Dean since 2015. This leadership transition coincides with the School's 20th anniversary, underscoring Duke-NUS' commitment to advancing the future of healthcare in Singapore and the region. Professor Patrick Tan appointed as Duke-NUS Dean to lead next era of medical innovation and education An internationally recognised cancer geneticist and clinician-scientist, Prof Tan is currently Senior Vice-Dean for Research at Duke-NUS, where he leads transformative research initiatives in genomics, precision medicine and biomedical innovation. He was one of the School's pioneer faculty members and has been involved in advancing its research strategy. Prof Tan has also been an active contributor in Singapore's research landscape, taking on roles including Executive Director of Precision Health Research Singapore (PRECISE), Senior Scientific Advisor at SingHealth and former Executive Director of the Genome Institute of Singapore. His leadership in integrating cutting-edge science with clinical applications has placed him at the forefront of Singapore's biomedical ecosystem. A firm believer in team science, Prof Tan is passionate about fostering interdisciplinary collaborations to solve Singapore's most pressing healthcare challenges. His ability to drive impactful change was recognised with the Exemplary Leader Award at the 2023 Public Sector Transformation Award Ceremony. Other awards include the President's Science Award (Team), American Association for Cancer Research (AACR) Team Science Award, and election to the American Society of Clinical Investigation and Association of American Physicians. A strong endorsement from Duke and NUS leadership Professor Tan Eng Chye, President of the National University of Singapore (NUS), said:"After a rigorous search within the University and globally, Patrick has been identified as the best candidate to lead Duke-NUS into its next chapter of growth as a key pillar in Singapore's healthcare and biomedical ecosystem. Patrick brings remarkable visionary leadership and profound expertise through years of dedicated service and contributions as researcher, scientist and educator. I am confident that his leadership and wealth of knowledge will bring the School towards higher levels of excellence, ensuring that our next generation of doctors, researchers and healthcare leaders are well-prepared to meet the challenges of tomorrow." Mr Goh Yew Lin, Chairman of the Duke-NUS Governing Board, said:"Patrick is first and foremost a world-class researcher, but what sets him apart is his deep understanding of how discovery and education must go hand in hand. As a graduate-entry medical school, Duke-NUS trains future clinicians who are not only skilled in patient care but also capable of asking bold questions and driving innovation. As Dean, he will ensure that the School's research priorities remain aligned with our national Research, Innovation and Enterprise (RIE) strategy, while strengthening translation and partnerships that attract industry collaborators and nurture a culture of innovation among our students." Professor Mary Klotman, MD, Executive Vice President for Health Affairs at Duke University, Dean of Duke University School of Medicine, and Chief Academic Officer of Duke Health, welcomed Prof Tan's appointment:"We are excited to work with Patrick as he takes on the mantle of the next Dean of Duke-NUS. A distinguished scientist and strategic leader, he brings a clear vision for how cutting-edge research and meaningful education can converge to improve lives. His commitment to collaboration and academic excellence makes him well-positioned to lead Duke-NUS into its next phase—strengthening our global partnership and expanding the School's contributions to advance health for all." The joint search committee to identify the successor for the role of Dean was chaired by Professor Aaron Thean, Deputy President (Academic Affairs) and Provost of the National University of Singapore, as well as Deputy Chairman of Duke-NUS Governing Board; and included faculty members from Duke-NUS, NUS, Duke University, SingHealth and the Duke-NUS Governing Board. Professor Tan's Vision for Duke-NUS Reflecting on his appointment, Professor Patrick Tan shared:"The healthcare landscape is evolving rapidly, driven by shifting demographics, intensifying demands on healthcare, and technological innovations. These are major challenges, but they also create huge opportunities. As Dean, I look forward to enhancing our long-standing Academic Medicine partnership with SingHealth and harnessing the collective strengths of Duke University and NUS, our parent institutions, to deepen our understanding of diseases and advancing medical solutions that will make a real difference to patients. "By combining the power of cutting-edge research, medical education and translational innovation, Duke-NUS is uniquely positioned to shape the future of medicine. Together with our valued partners, I am immensely grateful for the opportunity to work with our faculty, students, alumni and stakeholders to build on this strong foundation and drive the School's next stage of development in Singapore and the world." Honouring a Decade of Leadership: Professor Thomas Coffman Duke-NUS also expresses deep gratitude to Professor Thomas Coffman for his exceptional leadership over the past decade. A renowned physician-scientist in nephrology and cardiovascular research, Prof Coffman strengthened Duke-NUS' education and research landscape, ensuring that its training programmes remain rigorous and responsive to Singapore's evolving healthcare needs. He founded and built up the School's Cardiovascular and Metabolic Disorders Signature Research Programme as Director. Under his leadership, Duke-NUS also secured strategic funding to advance key research initiatives and played a critical role in Singapore's COVID-19 response, contributing to innovations such as rapid immune response testing. Prof Klotman expressed her appreciation for outgoing Dean, Prof Coffman, adding:"Tom has been an extraordinary bridge between Duke and Duke-NUS, deepening the ties between our institutions and reinforcing the values we share—academic excellence, collaboration and impact. Under his steady and visionary leadership, Duke-NUS has flourished as a beacon of innovation in education, research and clinical care. His legacy is not only reflected in the School's achievements but in the strength of our transcontinental partnership and global contributions to biomedical science." Mr Goh also expressed appreciation to outgoing Dean, Prof Coffman, saying:"Tom has led Duke-NUS through a defining decade with wisdom, vigour and steady resolve. He has not only guided the School's academic and research growth, but also shaped a culture that prizes excellence, collaboration and innovation. We are deeply grateful for his contributions and leadership, which have laid a strong foundation for the next chapter." Even as he steps down from his role as Dean, Prof Coffman will continue to lead key research initiatives, including DYNAMO, a multi-institutional study focussed on reducing the prevalence of diabetic kidney disease in Singapore and around the world. ### About Duke-NUS Medical School Duke-NUS is Singapore's flagship graduate-entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted 'Clinicians Plus' poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five Signature Research Programmes and ten Centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore's largest healthcare group. This strategic alliance has led to the creation of 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives. For more information, please visit www.duke-nus.edu.sg
Prize money of one million euros higher than the prize money for the Nobel Prize for Medicine Award honors researchers worldwide who have done pioneering work in medicine, biotechnology, or related fields GIEßEN, GERMANY - Newsaktuell - 17 January 2025 - The nomination period for the Broermann Medical Innovation Award has started. The prize, which will be awarded for the first time this year, is aimed at scientists worldwide who have carried out pioneering work in medicine, biotechnology, or related fields with their research. The nomination portal (www.broermann-award.org/nomination/) is open until March 1, 2025. At one million euros, the prize is more valuable than the Nobel Prize for Medicine, making it one of the most highly endowed awards for medical research worldwide. The international Broermann Medical Innovation Award recognizes research results that demonstrate a high level of innovation for clinical application and thus have the potential to improve the lives and health of millions of people worldwide. The prize is aimed at scientists whose research has been pioneering in the fields of medicine, biotechnology, or related sciences. The Broermann Medical Innovation Award was established in 2024 to honor the vision and commitment of Dr. Bernard große Broermann, the founder of the Asklepios Kliniken. The Broermann gemeinnützige GmbH sponsors the award, and the University Hospital Giessen and Marburg (UKGM) manages the organization. "With this award, we want to honor groundbreaking medical discoveries and highlight those whose research brings real improvements in the prevention or treatment of diseases," says Prof. Werner Seeger, Chairman of the Award Committee. For the Medical Director of the UKGM, Prof. Friedrich Grimminger, the unique prize reflects the clear conviction of the company founder: "Scientific excellence in medicine is always an international team effort, but without the genius of individual researchers, networks are limited in their impact. These key players and drivers of medical innovation should be promoted and recognized worldwide." Nomination process and deadlines Nominations for the Broermann Medical Innovation Award can be submitted until March 1, 2025. The incumbent Hessian Minister President will present the award in December 2025 at the Hessian State Chancellery in Wiesbaden. Further information on the award, the nomination criteria, and the selection process can be found at www.broermann-award.org. The issuer is solely responsible for the content of this announcement.
BANGKOK, THAILAND - Media OutReach Newswire - 27 December 2024 - The Ministry of Higher Education, Science, Research, and Innovation (MHESI), through the National Innovation Agency (Public Organization) or NIA, is forging ahead to support high-potential Thai startups and SMEs in the medical and health innovation sectors, granting them access to Germany, one of Europe's largest and most significant MedTech markets. As part of the 'Digital Innovation Business Development Programme for Connecting to International Markets and Funding in Europe,' NIA has selected eight outstanding Thai medical and health innovation startups and SMEs that have received prior NIA backing. These companies will showcase their cutting-edge innovations at Medica 2024 in the Federal Republic of Germany. The initiative aims to propel Thai medical innovations to global prominence and establish stronger footholds in the European market. Medica 2024 offers a critical platform for connecting Thai innovators with international opportunities, reinforcing Thailand's reputation as a global leader in medical and health innovation. Dr Krithpaka Boonfueng, Executive Director of the National Innovation Agency (Public Organisation), along with Professor Emeritus Dr Sirirurg Songsivilai, Chairman of the Board of Science, Research, and Innovation Promotion (GSRI), and a delegation of executives and staff from NIA, visited the exhibition booth showcasing the achievements of eight medical and health innovation startups supported by NIA. The visit took place at the Medica 2024 event in the Federal Republic of Germany. Dr. Krithpaka Boonfueng, Executive Director of the National Innovation Agency (Public Organization) or NIA, stated that NIA, in its role as a 'Focal Conductor of Innovation,' is dedicated to nurturing and enhancing the capabilities of Thai innovators to achieve sustainable growth. This commitment is guided by the '4G Approach': Groom: Fostering and strengthening the potential of Thai innovators. Grant: Providing financial mechanisms to develop and scale innovative businesses to market readiness. Growth: Accelerating the expansion of both startups and SMEs in the innovation ecosystem. Global: Propelling Thai innovators onto the international stage. Thailand's medical industry, a standout sector, benefits from one of the world's top-ranking healthcare systems. The global MedTech market is projected to soar to 775.8 billion US dollars by 2029, with Germany emerging as a particularly promising market. Germany's long-standing role as host of the world-renowned Medica trade fair for over 40 years underscores its importance. Recognised by experts as the largest medical trade exhibition globally, Medica attracts more than 6,100 exhibitors from 69 countries, solidifying its status as a pivotal platform for the medical and healthcare sectors. Dr Krithpaka added that the NIA is proud to participate in Medica 2024 under the theme 'Meet Health. Future. People,' hosted in the Federal Republic of Germany. As part of this prestigious event, eight outstanding Thai medical and healthcare innovation startups and SMEs, selected through a rigorous process, will showcase their pioneering solutions. These include: Eidy: A large language model (LLM) tailored for medical applications, distinguished by its specialised terminology and physician-like reasoning. It holds potential for developing chatbots designed to address specific medical queries. Ravis Technology: A platform for managing clinical research and data related to biopharmaceuticals, medical devices, and drugs. By leveraging technology to streamline data management, it saves time and costs. Pose Intelligence: A medical equipment management platform for hospitals, providing precise inventory control and central supply management. It reduces redundancy and minimises errors with its efficient systems. SOS Care: An innovative wound dressing made from silk protein combined with carboxymethyl cellulose (CMC) and glycerin. This flexible dressing promotes collagen production, accelerating wound healing. POPOLO: A device designed to band oesophageal varices caused by abnormal blood flow to the liver. This innovation enhances accessibility for Thai patients and reduces mortality rates. Orthopeasia: A cutting-edge platform for designing and producing spinal disc replacements using specialised software. Its innovation simplifies surgical procedures, ensuring smaller incisions, faster operations, and improved convenience for both surgeons and patients. BRE: A revolutionary two-step bathing sheet that eliminates the need for water and soap, providing a practical solution for patients unable to bathe, significantly enhancing their quality of life. Aquatrek Solution: A water treadmill, an advanced hydrotherapy device ideal for reducing the risks associated with exercise, particularly for the elderly. It minimises joint strain while supporting body weight, making it highly effective for rehabilitation and therapy. These eight groundbreaking innovations have garnered considerable interest from partners and potential collaborators across the United States, Europe, and Canada, seeking to exchange technologies and customer bases. Collaborative research opportunities, such as co-publishing with German academics, hosting researcher exchange programmes, or licensing specific or complete production technologies for German manufacturing, could significantly bolster the credibility of Thai medical devices. Research partnerships are a gateway to greater acceptance in the European market. Furthermore, studying attendee and exhibitor profiles at Medica 2024 offers invaluable insights for refining Thai innovations and devising strategic marketing approaches. These initiatives could stimulate investments, foster business matchmaking, and pave the way for cross-border collaborations, driving future advancements in medical innovation. Ms Maleepan Phasupong, from Ravis Technology Co Ltd, a developer of clinical research management platforms, shared her perspective on being selected to participate in the global medical and health innovation showcase Medica 2024. She highlighted that this prestigious event provided invaluable insights into the European market's overall needs, particularly in the realms of digital solutions, health and physical care devices, and diagnostic tools. Beyond helping Thai startups align their innovations with market demands, it serves as a pivotal starting point for achieving real business partnerships. By showcasing Thailand's research strengths, especially to Western countries increasingly interested in collaborative research with Thailand, the event bolstered international recognition. This growing interest is particularly evident in the West, where there is a notable trend towards exploring research partnerships in Thailand. During the event, the company secured discussions with five potential partners and clients, with follow-ups already underway. German STEM researchers, in particular, have expressed interest in exchanges with Thailand to reduce costs associated with services and production within Europe, such as clinical research expenses or medical device manufacturing. This highlights the tangible opportunities created through platforms like Medica, not only for networking but also for fostering deeper international collaboration and reducing operational costs. Mr Thanatpant Manosittisak of SOS Care Co Ltd, developer of silk-protein wound dressings, emphasised that Thai medical and health startups and SMEs have strong potential to thrive in global markets if provided with adequate support in terms of funding, resources, and technological development. He pointed out that Thailand's lower production costs, compared to developed nations, present a competitive advantage. However, government support is crucial to propel these startups and SMEs into forming international collaborations and expanding their market and business networks. Such backing enhances their credibility and strengthens confidence in the quality and innovation of Thai products on the global stage. Mr Thanatpant expressed hope that participating in Medica 2024 would enable his company to secure distributors across Europe, Asia, and the Middle East, thereby driving further international market expansion. Hashtag: #NIA The issuer is solely responsible for the content of this announcement.
Experts from Various Fields Gather to Discuss Cutting-Edge Medical Topics "Innovation+ Finance" Boosts Development of Medical Startups in Hong KongHONG KONG SAR - Media OutReach Newswire - 16 December 2024 - The Hong Kong Center for Cerebro-cardiovascular Health Engineering (COCHE) and College of Engineering, City University of Hong Kong proudly hosted the inaugural International Cerebro-cardiovascular Medical Innovation Summit (ICMIS) on December 12th. This flagship event brought together leading experts from industry, university, and research sectors to foster cross-disciplinary integration and collaboration among experts, to explore the path of innovation in the healthcare industry. During the summit, COCHE signed an MoU with Shanghai Innovation Bank to establish a partnership focused on fostering medical innovation. MoU Signing Ceremony Bringing Together Leaders from Industry, University and Research The inaugural International Cerebro-Cardiovascular Medical Innovation Summit was held at City University of Hong Kong, featuring prominent representatives from industry, university, and research sectors in the medical field from both Mainland and Hong Kong to explore and drive forward the frontiers of medical innovation. At the opening ceremony, Ms. Gracie NG, Chief of Staff and Acting Chief Corporate Development Officer, HKSTP, Prof. Johnny Chung Yin HO, Associate Vice-President (Enterprise), and Prof. LU Jian, Dean, College of Engineering, City University of Hong Kong, delivered speeches. Ms. Gracie NG said: "The collaboration between COCHE and Shanghai Innovation Bank is of great significance to the bank's business, greatly filling the industry gap in the cooperation between finance and the innovation technology sector. The importance of financial support for the success of startups is also fully reflected in this collaboration. The 'innovation + finance' cooperation model will promote the development of the Hong Kong technology innovation ecosystem." Prof. Johnny Chung Yin HO points: "City University of Hong Kong is the first local university in Hong Kong to promote the concept of 'One Health', in which we established the Institute of Digital Medicine in April of this year. The institute is dedicated to leveraging the university's research strengths in engineering, life sciences, artificial intelligence, and data science to provide innovative digital healthcare solutions. CityU will continue to cultivate more innovation and technology talent through the HK Tech 300 Program and the CityUHK Academy of Innovation, transforming the university's research outcomes into practical applications. Additionally, it will collaborate with the College of Engineering and COCHE to promote innovation and advancements in the healthcare sector. " Prof. LU Jian welcomed the guests on behalf of the summit's co-organizers, in which he mentioned: "The field of engineering plays a crucial role in connecting technological theory with real-world product applications. I am pleased that this summit provides a platform for experts and scholars from various fields to converge, communicate, and collaborate. The summit aims to promote interdisciplinary collaboration, transforming innovative ideas into practical solutions, and dedicate the contribution to the advancement of healthcare outcomes. " Collaboration with Shanghai Innovation Bank to nurture medical innovation During the opening ceremony, COCHE signed an MoU with Shanghai Innovation Bank, establishing a partnership in fostering the "New Quality Productive Forces" through the "innovation + finance" model. The MoU outlines a collaborative framework whereby COCHE will serve as a platform to facilitate the integration of technology innovation resources, including the business matching of relevant startups. This partnership seeks to establish a new win-win cooperation model for innovative enterprise incubation, merging science and technology with finance. Shanghai Innovation Bank will offer tailored debt financing, eco-system connections and various business empowerment initiatives for emerging medical technology startups and support their globalization strategies through collaborative efforts. Prof. Kannie WY CHAN, Centre Director of COCHE, commented: "Funding has always been a significant challenge for the translation of technical solutions into clinical use in Hong Kong. This collaboration provides a much-needed boost to our medical research efforts. By leveraging the 'innovation + finance' model, we can enhance the transformation of research outcomes, generate greater economic benefits, and advance the development of medical new quality productivity forces." Explore Pathways Towards Forward-Thinking Medical Innovation The summit featured two main sessions: "Digital Medical Innovations in Community" and "Ecosystem for Medical Innovations" where experts shared insights and engaged in discussions on a range of topics. Prof. LU Xiongwen, Dean of School of Management at Fudan University, delivered a plenary speech titled "Overview of Empowering Healthcare Enterprises through Management in China and Globally", where he mentioned: "The development of the health industry has enormous demand, and the entire sector is poised for significant growth. Whether in the field of cardiovascular health or the broader health industry, management empowerment is essential. From scientific and technical personnel to product development, and then to industrialization and marketization, the entire process requires management intervention to enable innovation and technological development through effective management. " Prof. Bryan YAN, Head of Division of Cardiology (Academic Affairs) at the Faculty of Medicine of The Chinese University of Hong Kong, delivered a keynote speech on "Stroke Prevention with Innovation". Prof. Bryan YAN highlights innovative strategies, like AI modelling and ECG monitoring for early detection and intervention, that can lead to stroke prevention being greatly enhanced. " By establishing health monitoring systems and raising awareness of risk factors, the goal is to identify individuals at risk of stroke as soon as possible. Integrating these technological solutions can significantly improve prevention efforts, leading to better health outcomes and a lower incidence of strokes." Prof. Bryan YAN said. In addition to serving as a platform for medical and university exchanges, the summit also arranged pitching sessions for different start-up incubated by COCHE to showcase their innovative medical technologies. Among them, Pyrocks Ultrasonics Company mainly produces an AI-Powered Ultrasound Patch for CVD Risk Assessment. This innovation can revolutionize the way people face and manage CVD by screening groups with varying levels of CVD risk, providing timely protection against CVD-related deaths. The inaugural International Cerebro-cardiovascular Medical Innovation Summit (ICMIS) successfully brought together experts, scholars, and industry representatives from various fields to discuss cutting-edge medical topics and promote multi-party collaboration. The summit organizer, COCHE, has taken the lead in the path of cardiovascular and cerebrovascular medical innovation, establishing a partnership with the Board of Directors of Yan Chai Hospital in Hong Kong. Through COCHE's innovative medical technologies and products, health screening activities have been conducted in multiple communities across Hong Kong, enabling residents to become aware of potential health risks in a timely manner. COCHE believes that the future of the healthcare sector relies on interdisciplinary collaboration, and the successful execution of this summit is expected to contribute valuable insights and support for the development of cardiovascular health medicine. Hashtag: #Cerebrocardiovascular#MedicalInnovationSummit #ICMISThe issuer is solely responsible for the content of this announcement.The 1st International Cerebro-cardiovascular Medical Innovation Summit (ICMIS)The International Cerebro-cardiovascular Medical Innovation Summit, a premier gathering of university, clinical, regulatory, industrial, financial, and other diverse fields, featuring leading experts from international realms. This summit aims to serve as a platform for exchange and sharing, fostering dialogue and collaborations among experts across various domains, to explore the path of innovation in the healthcare industry and drive forward the frontiers of medical innovation. Website: https://www.icmis2024.com Hong Kong Center for Cerebro-cardiovascular Health Engineering (COCHE)In collaboration with the University of Oxford and the Karolinska Institutet, Hong Kong Center for Cerebro-cardiovascular Health Engineering (COCHE) was established under City University of Hong Kong in 2020. The COCHE, supported financially by Innovation and Technology Commission (ITC), was admitted to Inno-Health cluster of InnoHK Programme which is a major R&D initiative of the Hong Kong Special Administrative Region Government. We are developing flexible sensing, biomedical and molecular imaging, nano-biosensing, and AI in health with the focus on innovative wearables that collect key vital signs, including but not limited to continuous blood pressure and electrocardiogram signals on an unobtrusive and real-time basis. The collected data is transmitted for further analysis and integration with other biomarkers, paving the way for the early detection and diagnosis of possible acute cerebro-cardiovascular diseases. Website: https://www.hkcoche.org/
A12 藝術空間
medical innovation
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
